Louisiana Ethics Administration Program
Home
Charges Search
EAB Decisions Search
My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2015-1382
LAEthics
>
Opinions
>
SearchableOpinions
>
2016
>
2015-1382
Metadata
Thumbnails
New Search
Entry Properties
Last modified
7/12/2021 11:15:47 AM
Creation date
3/21/2016 2:05:40 PM
Metadata
2015-1382
Fields
Template:
Opinion Item
Opinion Type
Advisory Opinion
Docket Number
2015-1382
Requesting Party
Dr. James Cardelli
Parties Involved
Microbiology and Immunology Dept.
Louisiana State University
Health Sciences Center
Shreveport
Innovative North Louisiana Experimental Therapeutics (INLET)
(SRA)
K94 Discoveries, Inc.
Segue Therapeutics, LLC
Secretary of State Office
Office of Sponsored Programs and Technology Transfer (OSPTT)
Decision Date
3/18/2016
Caption
Advisory opinion that a former professor at LSU Health Sciences Center in Shreveport, who was the Director of the Center’s Innovative North Louisiana Experimental Therapeutics (INLET) program, or the company of which he is president, would not be prohibited by the Louisiana Code of Governmental Ethics from funding research through a sponsored research agreement (SRA) with the Center/INLET, entering into licensing contracts with the Office of Sponsored Programs and Technology Transfer (OSPTT), or serving as an uncompensated advisor for K94 Discoveries, as he will not be conducting research that will be funded by SRAs with the Center/INLET and he will not be compensated for advising K94 Discoveries regarding its SRA with INLET.
Ethics Subject Matters
Post Employment
Participation
Prohibited Transactions
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
2
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
. 4 <br /> �,,, STATE OF LOUISIANA <br /> gyp,OF LOU''. <br /> F•�t`vo �jy'c DEPARTMENT OF STATE CIVIL SERVICE <br /> ;��;, LOUISIANA BOARD OF ETHICS <br /> 11';41.1%'' <br /> iiii,;�,�, ��III P.O.BOX 4368 <br /> ih <br /> 1.% BATON ROUGE,LA 70821 <br /> oN"' `' (225)219-5600 <br /> FAX:(225)381-7271 <br /> 1-800-842-6630 <br /> www.ethics.state.la.us <br /> March 21, 2016 <br /> Dr. James Cardelli <br /> 603 Avignon Ln <br /> Shreveport, LA 71115 <br /> Re: Ethics Board Docket No. 2015-1382 <br /> Dear Dr. Cardelli: <br /> The Louisiana Board of Ethics, at its March 18, 2016 meeting, considered your request <br /> for an advisory opinion regarding the application of the post-employment restrictions set <br /> forth in the Code of Governmental Ethics. You provided the following background <br /> information for consideration in connection with your request: <br /> You were employed as a professor in the Microbiology and Immunology Department of <br /> the Louisiana State University Health Sciences Center in Shreveport (Center) from 1985 <br /> until December 31, 2015. In addition to teaching classes, you were responsible for <br /> running a research laboratory. Separate and apart from your role as a professor, you also <br /> served as the Director of the Center's Innovative North Louisiana Experimental <br /> Therapeutics (INLET) program from 2012 through 2015, for which you received no <br /> additional compensation. INLET consists of a multi-institutional program focused on <br /> discovering and marketing natural products and repurposed drugs that are used to treat <br /> one human disease and repositioning them to treat other diseases in humans. The <br /> research conducted as part of INLET includes independent research, federally-supported <br /> research, and company-sponsored research programs. Finally, as Director of INLET and <br /> the principal investigator, you wrote the first sponsored research agreement (SRA) <br /> funded by K94 Discoveries, Inc., a biotechnology company, that ended in early 2015. <br /> As President of Segue Therapeutics, LLC, a biotechnology company that you registered <br /> with the Secretary of State's Office on January 6, 2016, you are currently involved in <br /> acquiring first round seed money to develop and commercialize existing drugs for new <br /> medical purposes. Some of this money will be sent to the Center/INLET in the form of <br /> SRAs to perform research to further develop repurposed drugs for treatment of human <br /> diseases. However, you will not be conducting the research that will be funded by the <br /> SRAs. Additionally, Segue Therapeutics, LLC, intends to license technologies that you <br /> developed while employed with the Center. Legal counsel will negotiate the SRAs with <br /> the Center and the licensing contracts with the Center's Office of Sponsored Programs <br /> and Technology Transfer (OSPTT). Finally, you will serve as an uncompensated advisor <br /> AN EQUAL OPPORTUNITY EMPLOYER <br />
The URL can be used to link to this page
Your browser does not support the video tag.